# SPINRAZA Clinical Trial Data
Keywords: SPINRAZA, SMA, clinical trials, ENDEAR study, SHINE study, survival, motor milestones, motor function, safety outcomes, real-world evidence

> This page provides detailed information about SPINRAZA (nusinersen), including its clinical trial data, survival and motor function outcomes, safety results, and real-world evidence supporting its benefits for patients with spinal muscular atrophy (SMA).

## Details
- [Randomised Controlled Trials](#): Overview of trials involving over 300 patients with infantile-onset (Type I), later-onset (Type II/III), and other SMA populations treated with SPINRAZA.
- [ENDEAR Study](#): Key study on infantile-onset SMA, focusing on survival and motor milestones as primary and secondary endpoints.
- [SHINE Study](#): Long-term follow-up study providing additional insights into SPINRAZA's efficacy and safety.
- [Safety Outcomes](#): Comprehensive evaluation of SPINRAZA's safety profile across various SMA populations.
- [Real-World Evidence](#): Extensive studies demonstrating SPINRAZA's benefits for children, teenagers, and adults with SMA.